NCT03258840 is a NA clinical trial of EPA Supplement in Diabetes Mellitus Type II, sponsored by Tehran University of Medical Sciences.

Who is sponsoring NCT03258840?

NCT03258840 is sponsored by Tehran University of Medical Sciences.

What drugs are being tested in NCT03258840?

Interventions in NCT03258840: EPA Supplement, EPA Placebo.

What condition does NCT03258840 study?

NCT03258840 studies Diabetes Mellitus Type II.

Is NCT03258840 still recruiting?

NCT03258840 is currently completed. Last updated 22 August 2017.

Last reviewed 2017-08-22 · How we verify

NCT03258840

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of EPA on the Serum Activities of Paraoxonase 1, Homocystein, Thiolactonase and Some Indicators of Vascular Inflammation and PON2 Gene Expression in PBMC Ofthe Patients With Type II Diabetes

Completed NA Last updated 22 August 2017

What this trial tests

NA trial testing EPA Supplement in Diabetes Mellitus Type II in 36 participants. Completed in 1 August 2014.

Timeline

1 January 2013

Primary endpoint
1 April 2013

1 August 2014

Quick facts

Lead sponsor	Tehran University of Medical Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	36
Start date	1 January 2013
Primary completion	1 April 2013
Estimated completion	1 August 2014
Sites	1 location across Iran

Drugs / interventions tested

EPA Supplement
EPA Placebo

Conditions studied

Diabetes Mellitus Type II — all drugs for Diabetes Mellitus Type II →

Sponsor

Tehran University of Medical Sciences

Who can join

Adults 35 to 50, any sex, with Diabetes Mellitus Type II. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

HbA1c
Time frame: Change from Baseline at 8 weeks after the intervention
Hemoglobin A1c (HbA1c) measurement by related kits according their protocols

Sponsor's own description

The aim of this study is to determining of the effects of Eicosapentaenoic acid (EPA) supplementation on serum activities of Paraoxonase-1 and Homocystein thiolactonase, and serum levels of some indicators of vascular inflammation, and the gene expression of PON2 in the peripheral blood mononuclear cell (PBMC) in the patients with type II diabetes mellitus.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Eicosapentaenoic Acid Supplementation on Paraoxonase 2 Gene Expression in Patients with Type 2 Diabetes Mellitus: a Randomized Double-blind Clinical Trial.
Golzari MH, Javanbakht MH, Ghaedi E, Mohammadi H, et al · · 2019 · cited 10× · PMID 30746344 · DOI 10.7762/cnr.2019.8.1.17
Effects of eicosapentaenoic acid supplementation on heat shock protein 27, glycemic status and anthropometric indices in type 2 diabetes patients.
Ghaedi E, Sharifdini JG, Javanbakht MH, Mohammadi H, et al · · 2023 · cited 1× · PMID 37255775 · DOI 10.1007/s40200-022-01083-3

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus Type II

Currently open trials in the same condition.

NCT07011147 — Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery · NA · recruiting

Other Tehran University of Medical Sciences trials

Trials by the same sponsor.

NCT07305883 — Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain · Phase 3 · not yet recruiting
NCT06876194 — The Effect of Music on the Sedation Quality Among Children in the Emergency Department. · Phase 3 · completed
NCT06721273 — Iodine Supplementation and Fertility Parameters · NA · not yet recruiting
NCT07014397 — Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth · NA · completed
NCT06615934 — Effects of Aerobic and Resistance Exercises on Inpatients Liver Transplantation Recipients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03258840 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tehran University of Medical Sciences
Last refreshed: 22 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03258840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing